The phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55), which evaluated the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer who have received one to three prior lines of therapy, demonstrated statistically significant improvements in progression free survival, overall response rate, and overall survival compared to chemotherapy.
In a study published in Cancer Discovery, researchers from the Wistar Institute reported a key mechanism as to how p53 suppresses tumors. By comparing the mechanisms of wildtype and variant p53, the researchers discovered the mechanism by which p53 triggers immune function that, in turn, kills the tumor.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
Approximately one-third of patients with non-small-cell lung cancer who were treated with the targeted therapy Lumakras (sotorasib) survived for at least two years after enrolling in a large clinical trial that evaluated the drug—significantly longer than what can be expected from patients treated with standard chemotherapy.
A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.
ImmunityBio Inc. and NCI are partnering to open a clinical trial to study ImmunityBio’s investigational Tri-Ad5 vaccine combination (Adenovirus 5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803, an immune-enhancer, for people with Lynch syndrome.
Results of the Investigation of Novel Surgical Imaging for Tumor Excision (INSITE) pivotal trial highlight the safety and effectiveness findings of Lumicell’s pivotal trial of its investigational Lumicell Direct Visualization System to identify residual breast cancer following removal of the primary specimen during initial lumpectomy.
Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.
In a translational study from UCLA Jonsson Comprehensive Cancer Center, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies.
A team of University of Florida researchers has developed a promising new CRISPR-powered method for noninvasive blood tests that could help clinicians diagnose cancer at earlier stages.
